ACE and COVID-19: Initial concerns that the use of RAAS inhibitors, namely angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB), may increase the risk or severity of COVID-19 via upregulation of ACE2 have been refuted [168,169,170], and the risk of harm from ACEi or ARB use in the setting of COVID-19 has been clearly disproven [171,172,173,174,175,176,177,178,179].